#Lymphocyte Activation Gene - 3 Protein Market Share

[fairfield-research]

Oncology Drugs Market Growth, Trends, Size, Share, Demand And Top Growing Companies 2031

In a landscape where the battle against cancer rages on, advancements in healthcare systems, public health measures, and novel pharmaceutical therapies have ushered in a new era of hope. According to the National Cancer Institute, the United States saw an estimated 1,806,590 new cancer cases and approximately 606,520 deaths due to the disease in 2020. However, over the past five decades, cancer survival rates have soared from 50% in 1970 to an impressive 70%, thanks to a trifecta of progress.

For more information: https://www.fairfieldmarketresearch.com/report/oncology-drugs-market

Unprecedented Growth Trajectory: The global oncology therapy sales are forecasted to surpass US$ 300 billion by 2026, with oncology contributing 21.7% to total pharmaceutical sales. Fueling this growth are the top 10 pharmaceutical companies, which have declared oncology as their key focus area, driving multibillion-dollar M&A deals and strategic collaborations. Pfizer's acquisition of Array BioPharma for US$11 billion in 2019 and AbbVie's strategic partnership with Genmab for a bispecific antibody development deal worth US$3 billion are testament to this focus.

Diverse Indications Drive Demand: While oncology represents over 20 different indications, a significant portion of revenue stems from just five of them: breast cancer, multiple myeloma, non-small-cell lung carcinoma (NSCLC), prostate cancer, and non-Hodgkin's lymphoma (NHL), which collectively accounted for approximately 65% of the market in 2020. Moreover, with breast, lung, and colorectal cancers expected to collectively account for ~50% of all new cancer diagnoses by 2026, the demand for innovative therapies continues to surge.

Disruptive Trends Reshape Landscape: Innovation in oncology is accelerating, with disruptive technologies such as cell therapy, RNA therapy, viral vectors, and stem cell therapy gaining traction. Recent approvals of CAR-T cell therapies like Kymriah and Yescarta for acute lymphocytic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL) respectively signal a new frontier in cancer treatment. Precision medicine is also driving progress, with over 160 oncology biomarkers approved by 2019, paving the way for more targeted and effective therapies.

Impact of COVID-19: Despite remarkable progress, oncology has been among the worst-hit therapeutic areas amid the COVID-19 pandemic. Decreased demand for physician-administered products, disruptions in cancer screenings, and a decline in new clinical trials have posed significant challenges. However, the industry remains resilient, adapting to the evolving landscape and ensuring continued innovation.

Immuno-Oncology Leads the Way: Immuno-oncology sales are expected to soar to ~US$ 95 billion by 2026, with agents and protein kinase inhibitors comprising ~65% of sales. With over 550 active cell- and gene-therapy agents under clinical development, the future of cancer treatment looks promising. Investments in combination studies and the exploration of new mechanisms underscore the industry's commitment to advancing immuno-oncology therapies.Roche and Keytruda: Leading the Charge: In a highly concentrated market where the top 10 companies capture over 75% of the market value, F. Hoffmann-La Roche AG (Roche) and Merck & Co. stand out as leaders. While Roche maintains its global leadership position, Merck's Keytruda is poised to become the world's top-selling oncology

[expertofmarketinsights-blog]

Lymphocyte Activation Gene - 3 Protein Market Shows Expected Growth from 2018-2026

Immune checkpoint receptors such as lymphocyte activation gene - 3 (LAG-3) protein are found on cell surface of effector T cells and regulatory T cells (Tregs). T cells are a type of white blood cells that eliminate unhealthy or foreign cells that enter the immune system. Function of lymphocyte activation gene - 3 protein is to control T cell response, activation, and growth. Lymphocyte activation gene - 3 turns off the immune response when a T cell is activated to eliminate a target cell. This prevents the T cells from harming healthy cells. Moreover, lymphocyte activation gene - 3 protein is associated with T cell exhaustion in which the T cells become desensitized and lose their ability to function.

LAG-3 is closely associated with regulation of cytotoxic T cells and regulatory T cells, which has attracted attention of researchers and manufacturers as a therapeutic target against cancer. In cancers, lymphocyte activation gene - 3 expressing exhausted cytotoxic t cells and regulatory T cells (Tregs) are found to be gathered at tumor locations. Recent studies reported that inhibiting LAG-3 functions allows T cells to regain their cytotoxic function and affect tumor growth. There are several LAG-3 protein antibodies in the clinical trials, which are expected to further advance in clinical trials over the forecast period.

Lymphocyte Activation Gene - 3 Protein Market Drivers

Several drugs in clinical trials that target the LAG-3 protein, is expected to be a major factor contributing in global lymphocyte activation gene - 3 protein market growth over the forecast period. These drugs are still in the clinical trials in different phases. For instance, in 2017, BMS-986016 (Relatlimab)—developed by Bristol-Myers Squibb—in combination with Opdivo (nivolumab), effectively aided in treatment of advanced melanoma that was previously treated with anti-PD-1/PD-L1 therapy. The drug is in phase II clinical trial and its estimated study completion date is March 16, 2022.

Moreover, several other drugs such as MGD013 sponsored by MacroGenics (estimated study completion date - August 2022) and IMP321 (eftilagimod alpha) by Immutep (estimated study completion date is August 2019) that are in Phase 1 clinical trials, is expected to be a major factor contributing in global LAG-3 protein market growth over the forecast period.

Lymphocyte Activation Gene - 3 Protein Market Regional Insights

North America is expected to witness significant growth in the LAG -3 protein market over the forecast period. Robust pipeline of LAG-3 protein antibodies and the increasing demand for such drugs is expected to facilitate growth of the market, in the U.S. For instance, Bristol-Myers Squibb has Relatlimab in phase II clinical trials and Regeneron Pharmaceuticals Inc., in collaboration with Sanofi, has REGN3767 in phase I clinical trials, 2017.

High prevalence of various types of cancer in North America, Europe, and Asia Pacific region is expected to be a major factor contributing growth of the lymphocyte activation gene - 3 protein market over the forecast period. According to European Union (EU), in 2014, almost 1/3rd million people died from cancer in the EU-28. Moreover, manufacturers are focused on conducting clinical trials in these regions to expand their potential customer base.

Lymphocyte Activation Gene - 3 Protein Market Key Player

Key players operating in the global lymphocyte activation gene - 3 protein market include, Bristol-Myers Squibb, Icell Kealex Therapeutics, Incyte Corporation, MacroGenics, Inc., GlaxoSmithKline Plc, Crescendo Biologics Ltd, Regeneron Pharmaceuticals Inc., Sutro Biopharma Inc., Symphogen A/S, and Immutep Ltd.

Ask For Sample Copy Of This Business Research Report : https://www.coherentmarketinsights.com/insight/request-sample/2027

Lymphocyte Activation Gene 3 Protein Market Taxonomy

The global lymphocyte activation gene - 3 protein market is segmented on the basis of drug, cancer type, and region.

By Drug -

BMS-986016 (Relatlimab)

IMP321

IMP701

MGD013

Others

By Cancer Type -

Breast Cancer

Melanoma

Solid Tumors

Others

 About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

 Contact Us:

Mr. Shah Coherent Market Insights 1001 4th Ave,  #3200  Seattle, WA 98154 Tel: +1-206-701-6702 Email: sales@coherentmarketinsights.com

[globalmarketresearchblog-blog]

Lymphocyte Activation Gene 3 Protein Market- Size, Share, Outlook, and Forecast till 2026

Lymphocyte-activation gene 3, also known as LAG-3, is a protein that is has diverse biological effects on the functioning of T cells. This protein was first discovered in 1990. LAG-3 is an immune checkpoint receptor, and is thus used as the target of various drug development programs.

Increasing prevalence of chronic diseases such as cancer and autoimmune diseases such as AIDS are expected to increase the demand for treatment measures. This in turn, is expected to increase demand for lymphocyte-activation gene 3 protein, thus boosting growth of the lymphocyte-activation gene 3 market. Increasing number of pharmaceutical companies are seeking to develop new treatments for cancer and autoimmune disorders is expected to boost growth of the Lymphocyte-activation gene 3 protein market.

Get Sample copy of research report: https://www.worldwidemarketreports.com/sample/196105

Prima BioMed Ltd is a biotechnology company that is engaged in research, development, and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment with its core technologies based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response.

The lymphocyte-activation gene 3 market is gaining significant traction, owing to increasing research and development activities by various key players in the market.

F-star, a clinical-stage biopharmaceutical company developing novel bispecific antibodies—announced successful dosing of the first patient with FS118 in a Phase I clinical trial. FS118 is a first-in-class bispecific antagonist simultaneously targeting LAG-3 (Lymphocyte-Activation Gene 3) and PD-L1 (Programmed Death-Ligand 1), two immune checkpoint molecules involved in tumor growth through attenuation of immune surveillance. FS118 showed potent anti-cancer activity in preclinical models, as recently presented by F-star at the 2018 AACR meeting.

Get Best Discount on Research Report: https://www.worldwidemarketreports.com/discount/196105

In March 2015, a breakthrough in immunotherapy was recorded when the FDA approved Nivolumab as a second line treatment for metastatic lung squamous carcinoma. Nivolumab was previously known to be indicated for use among patients suffering from melanoma that is either not resectable or had not responded to other therapies.6, 7, 8, 10, not all PD‐1 or PD‐L1 positive patients show positive outcomes through this treatment of anti‐PD‐1 or PD‐L1 monoclonal antibody.

In 2014, GSK successfully was able to receive positive outcomes from its product GSK2831781, an anti LAG-3 drug, which proved to demonstrate positive results among healthy people and patients suffering from plaque psoriasis.

Browse more detail information about Lymphocyte Activation Gene 3 Protein Market Report at: https://www.worldwidemarketreports.com/market-insights/lymphocyte-activation-gene-3-protein-market

Bristol-Myers Squibb, also known as BMS, developed an Anti‐LAG‐3 drug. The company announced in 2017, that it successfully completed its preliminary efficacy trial for BMS-986016—an investigational anti-lymphocyte-activation gene 3 (LAG-3) therapy—in combination with Opdivo (nivolumab) for advanced melanoma. These patients were previously treated with anti-PD-1/PD-L1 therapy, however, showed no progress. While treatment with the new drug helped stop relapse melanoma among these patients. This development in turn, is expected to boost growth of the lymphocyte-activation gene 3 market.

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends. Worldwide Market Research’s well-researched inputs that encompass domains ranging from IT to healthcare enable our prized clients to capitalize upon key growth opportunities and shield against credible threats prevalent in the market in the current scenario and those expected in the near future.

Contact Us:

Mr. Shah

Worldwide Market Reports

Tel: +1 415 871 0703

Email: sales@worldwidemarketreports.com

Visit our Website for More Details: https://www.worldwidemarketreports.com

Visit our new Website: https://industrychronicle.com

[expertofmarketinsights-blog]

Lymphocyte Activation Gene - 3 Protein Market Trends Research And Projections For 2018-2026

Lymphocyte Activation Gene – 3 Protein Market Trends Research And Projections For 2018-2026

Immune checkpoint receptors such as lymphocyte activation gene – 3 (LAG-3) protein are found on cell surface of effector T cells and regulatory T cells (Tregs). T cells are a type of white blood cells that eliminate unhealthy or foreign cells that enter the immune system. Function of lymphocyte activation gene – 3 protein is to control T cell response, activation, and growth. Lymphocyte…